Toinv if we can only succeed in Phase 3, Covid-19, CORAL Study to give Pfizer some competition. Pfizer predicts it will make at least $22 billion in sales from the pill Paxlovid this year. It's never too late to get in the Covod-19 race. Currently, the pill is only available under an emergency authorization. Still room for Apabetalone to shine if management can get their act together. Aversana needs to get involved big time if they want to get paid what they are owed and then some. 

We need to stop dwelling on Don and focus on what counts going forward. 

Koo